by Elana Gotkine For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use, according to a research letter published online March 6 in JAMA Network Open. Omer S. Ashruf, from Northeast Ohio Medical University in Rootstown, and colleagues...
Tag: <span>Type 2 Diabetes</span>
Post
GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients
By Tarun Sai LomteReviewed by Susha Cheriyedath, M.Sc.Mar 9 2025 Could a diabetes drug slash your cancer risk? New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing blood sugar. Glucagon-like peptide 1 (GLP-1, 7-36) molecule — a potent antihyperglycemic hormone, neuropeptide, and incretin. Research letter: Hematologic Cancers Among Patients With...
Post
New insights into insulin action: Dynamic signaling network offers therapeutic approaches for type 2 diabetes
by Deutsches Zentrum fuer Diabetesforschung DZD Time-resolved phosphoproteomics analysis of insulin action in human skeletal myotubes. Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-56335-6 Researchers from the German Diabetes Center (DDZ) and the Heinrich Heine University Düsseldorf (HHU) have studied the temporal pattern of insulin action on protein kinases in human muscle cells in detail for the first time....
Post
Type 2 diabetes: New plant-based pill shows promise in human trials
By Paul McClure March 03, 2025 A new plant-based pill significantly improved blood sugar control in type 2 diabetics Depositphotos and generative AI View 2 Images A clinical trial to test the effectiveness of a new, plant-based oral drug to treat type 2 diabetes has produced some promising results. The drug significantly improved blood glucose control and...
Post
AI analysis of eye images offers a window to kidney health in type 2 diabetes
by University of Dundee Credit: Ksenia Chernaya from Pexels New University of Dundee research has revealed that using artificial intelligence (AI) to analyze photos taken during routine diabetes eye screenings provides a window into kidney health. The innovative new approach can predict whether people with type 2 diabetes are likely to develop chronic kidney disease years before symptoms...
Post
Discovery of rare gene variants provides window into tailored type 2 diabetes treatment
Medications don’t work for everyone, highlighting need for targeted drugsPeer-Reviewed Publication University of Oklahoma FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail image: Dharambir Sanghera, Ph.D., is a professor of pediatric genetics at the University of Oklahoma College of Medicine.view more Credit: University of Oklahoma OKLAHOMA CITY – A new study published in Communications Medicine, a Nature publication, details the discovery of rare gene variants that increase the prevalence...
Post
Leisure-time physical activity is key for type 2 diabetes risk reduction, research shows
by Elsevier Credit: CC0 Public Domain Researchers have found that engaging in moderate to vigorous physical activity during leisure time, regardless of occupational physical activity, is associated with a reduced risk of type 2 diabetes. A combination of sedentary leisure-time activity and demanding occupational activity may increase the risk. Findings from a novel study, appearing in the American Journal...
Post
Can type 2 diabetes be reversed? Experts say ‘yes’
by Serena Crawford, Yale University Credit: Unsplash/CC0 Public Domain More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body’s cells not responding to insulin properly, leading to high blood sugar levels. Due to the concomitant increase in the prevalence of obesity, type 2 diabetes is rising across the U.S. and...
Post
AI uses simple glucose monitor data to predict and identify subtypes of type 2 diabetes
by Hanae Armitage, Stanford University Metabolic subphenotyping study overview. Credit: Nature Biomedical Engineering (2024). DOI: 10.1038/s41551-024-01311-6 Diabetes has long been lumped into two categories—type 1, which often appears in childhood, or type 2, which is associated with obesity and typically develops later in life. But scientists have learned that not all patients with type 2 diabetes are the...
Post
Do GLP-1s Lower VTE Risk in People With Type 2 Diabetes?
Kate Johnson December 11, 2024 03 Added to Email Alert Glucagon-like peptide 1 (GLP-1) receptor agonists led to a significant reduction in the risk for venous thromboembolism (VTE) among individuals with type 2 diabetes compared with dipeptidyl peptidase 4 (DPP-4) inhibitors, a recent analysis indicated. Overall, GLP-1 agonist use was associated with a 20% reduction...